Ganga Pharmaceuticals Limited

539680

INE615T01017

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:55 24/06/2024 BST			5-day change	1st Jan Change
24.67 ^INR	-.--%		-.--%	-13.41%

05-16	Ganga Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
01-19	Ganga Pharmaceuticals Limited announced that it has received INR 17.0625 million in funding from Lenus Finvest Pvt Ltd, Plutus Capital Management Llp	CI

874,550 equity shares of Ganga Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 23-FEB-2019.

February 22, 2019

874,550 equity shares of Ganga Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 23-FEB-2019. These shares will be under lockup for 1102 days starting from 17-FEB-2016 to 23-FEB-2019.

Latest news about Ganga Pharmaceuticals Limited

Ganga Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-16	CI
Ganga Pharmaceuticals Limited announced that it has received INR 17.0625 million in funding from Lenus Finvest Pvt Ltd, Plutus Capital Management Llp	01-18	CI
Ganga Pharmaceuticals Limited announced that it expects to receive INR 21 million in funding from Lenus Finvest Pvt Ltd, Plutus Capital Management Llp	12-03	CI
Ganga Pharmaceuticals Board to Consider Issuing Equity, Convertible Warrants to Raise Funds	11-27	MT
Ganga Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended September 30, 2023	11-08	CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2023	22/08/23	CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended September 30, 2022	11/11/22	CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2022	25/05/22	CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2021	28/06/21	CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended September 30, 2020	05/11/20	CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2020	27/06/20	CI
Ganga Pharmaceuticals Limited Announces Management Changes	25/05/20	CI
Ganga Pharmaceuticals Limited Announces the Appointment and Re-Designation of Sanjay Kulkarni as Executive Director	27/08/19	CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2019	13/05/19	CI
874,550 equity shares of Ganga Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 23-FEB-2019.	22/02/19	CI
Ganga Pharmaceuticals Limited Reports Unaudited Standalone Earnings Results for the Half Year Ended September 30, 2018	05/11/18	CI
Ganga Pharmaceuticals Limited Appoints Anagh B. Sharma as Chief Financial Officer	06/09/18	CI
Ganga Pharmaceuticals Limited Announces Resignation of Ganesh Jyothimani Paradeshi, Chief Financial Officer	30/08/18	CI
Ganga Pharmaceuticals Limited Announces Audited Standalone Earnings Results for the Half Year and Full Year Ended March 31, 2018	28/05/18	CI
Ganga Pharmaceuticals Limited Reports Unaudited Standalone Earnings Results for the Half Year Ended September 30, 2017	09/11/17	CI
Ganga Pharmaceuticals Limited Reports Audited Earnings Results for Fourth Quarter and Full Year Ended March 31, 2017	22/05/17	CI
2,106,950 equity of Ganga Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 23-FEB-2017.	22/02/17	CI
Ganga Pharmaceuticals Limited Reports Unaudited Standalone Earnings Results for the Half Year Ended September 30, 2016	08/11/16	CI
Ganga Pharmaceuticals Limited Reports Audited Standalone Earnings Results for the Half Year and Full Year Ended March 31, 2016	26/05/16	CI
Ganga Pharmaceuticals Limited Appoints Priti Kothari Bhaiya as Company Secretary and Compliance Officer to Replace Mustafa Shabbir Badami	22/03/16	CI

Chart Ganga Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Ganga Pharmaceuticals Limited is an India-based company, which is engaged in the production of ayurvedic medicines. The Company is also into marketing and distribution of ayurvedic medicines. It offers ayurvedic medicines in various categories, including acidity, antidandruff, antioxidants, blood purifier and skin disorder, constipation, cough and cold, dental care, diarrhea, ear care, female tonic, hair care, hemorrhoids and piles, indigestion, iron tonic, joint pains, kidney stone, liver disorder, rejuvenation tonic, sleep inducers, and herbal cosmetics. Its products include Asuka tablets, Dendroil, Ashwo tablets - tonic for body and mind, Raktaj tablets/syrup - for skin disorders, Nirmalaya (proprietary) - relieves constipation, Khadira tablets (80 mg.) (A.S.S) - relieves cough, Danta Doshahar Manjan - gum and teeth protective, Holetrica capsule - checks diarrhea and corrects digestion, Karnaraj drops (proprietary) - ear drops, Femoherb syrup/tablets, and Mahabhrungraj oil.

Sector

Pharmaceuticals

Calendar

06/11/2024 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GANGA PHARMACEUTICALS LIMITED	-13.41%	1.43M
ELI LILLY AND COMPANY	+54.07%	816B
NOVO NORDISK A/S	+38.59%	634B
JOHNSON & JOHNSON	-7.05%	351B
MERCK & CO., INC.	+15.44%	323B
ABBVIE INC.	+5.72%	293B
ASTRAZENECA PLC	+13.40%	238B
ROCHE HOLDING AG	+0.61%	222B
NOVARTIS AG	+13.24%	218B
AMGEN INC.	+7.42%	167B